NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

The Use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis: Interim Policy Guidance. Geneva: World Health Organization; 2013.

Supporting internet materials

Expert Group Meeting report, including PICO question (PDF, 1.3M)

The contribution of bedaquiline to the treatment of MDR-TB – synthesis of publicly available evidence, Bernard Fourie, South Africa (PDF, 966K)

Evaluation of sputum culture conversion as a surrogate marker of MDR-TB treatment outcome, Ekaterina Kurbatova et al, CDC, Atlanta, GA, United States;

Cost-effectiveness of introducing bedaquiline in MDR-TB regimens – an exploratory analysis, Anna Vassall, London School of Hygiene and Tropical Medicine, London, United Kingdom (PDF, 283K)

Available here: http://www.who.int/tb/challenges/mdr/bedaquiline/en/index.html

Copyright © World Health Organization 2013.

All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: tni.ohw@sredrokoob).

Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO web site (www.who.int/about/licensing/copyright_form/en/index.html).

Bookshelf ID: NBK154131
Contents